DermaCann, a proprietary blend of plant based compounds containing cannabidiol (CBD) is in development for anti-inflammatory and immune support for dogs with dermatological conditions. It was tested in a cohort of dogs with Canine Atopic Dermatitis (CAD) in a double blind, randomised, placebo controlled study 2 DermaCann formulations. The study included 13 eligible dogs with CAD. 8 dogs were allocated to DermaCann treatments and 5 received placebo. All dogs were dosed twice daily for 56 days. CADESI-4 scoring, skin and coat assessments and blood sampling for inflammatory biomarker and clinical chemistry were completed at day 0, 28 and 56 of treatment. The dog owners completed pruritus and quality of life scoring every 2 weeks. A 51%, significant average reduction in CADESI-4 scores was seen for DermaCann treated dogs. This result was similar between DermaCann formulations and compared with no improvement in CADESI-4 scores for the placebo treated dogs. This clinical reduction in inflammation was also supported by IL-8 and CCL2 increases in the placebo treated dogs, while these chemokines were decreased in the DermaCann treated dogs after 56 days. There was no significant difference between treatment groups for pruritus. DermaCann was well tolerated by dogs, with few adverse events and it is expected that long term use of DermaCann will be safe in dogs. The combination of these ingredients with CBD provides a unique, well tolerated, plant based nutraceutical to include in the management of inflammation in dermatological conditions such as CAD.